Page 2531 - Williams Hematology ( PDFDrive )

2502 Index Index 2503

Venetoclax (ABT-199) Vesicle-associated membrane protein-2, 926, Vindesine, for diffuse large B-cell lymphoma,
for chronic lymphocytic leukemia, 1539 1010 1628
for mantle cell lymphoma, 1660t V genes, 1163, 1167f, 1169, 1170, 1177, 1708 Vinorelbine, for Hodgkin lymphoma, 1616
Venipuncture, 2367 VH3/JH4, 1786 Viral infections. See also specific viruses
Venography, 2269–2270 VH–34, 1554, 1557 aplastic anemia and, 518
Venoms, 970 VHL. See under Von Hippel-Lindau disseminated intravascular coagulation
Venoocclusive disease with VHL, polycythemia and, 510, 876–877, 877f, and, 2207
immunodeficiency (VODI), 1222 878f, 882t erythema multiforme and, 2106
Venous thrombosis/thromboembolism, Vibrio cholerae, 2340 after hematopoietic cell transplantation,
2267–2278 Vibrio parahaemolyticus, 2340 369–370
in antiphospholipid syndrome, 2238, Vimentin, 1837 immune cell therapy of. See Immune cell
2238f, 2244 Vinblastine, 325–326. See also ABVD therapy (adoptive cellular therapy),
vs. arterial thrombosis, 2291t regimen; Stanford V regimen of viral diseases
in chronic myeloproliferative neoplasms, for adult Langerhans cell histiocytosis, immune thrombocytopenic purpura and,
2079–2081 1108 2009
clinical course, 2273 adverse effects, 326, 1108 in immunocompromised host, 383–384
clinical features, 2268–2269. See also for immune thrombocytopenia, 2007 immunodeficiencies with increased
Deep vein thrombosis (DVT); for juvenile xanthogranuloma, 1112 susceptibility to, 1230
Pulmonary embolism for Langerhans cell histiocytosis, 1107 mast cells/basophils in host response to,
consultative approach to, 46–47 mechanism of action, 325 970
definition and epidemiology, 2267–2268 pharmacology, 325–326 prevention, 389
in disseminated intravascular coagulation, resistance to, 319t purpura and, 2104, 2105f
2204, 2205t stomatocytosis and, 684 transmission in factor VIII products,
etiology and pathogenesis, 2268 for α-heavy-chain disease, 1808 2126
in heparin-induced thrombocytopenia, Vinca alkaloids. See Vinblastine; Vincristine treatment, 386, 387t
2028 Vincristine, 325–326. See also BEACOPP Viral vectors, for gene therapy
in immune thrombocytopenia, 2002 regimen; CHOP regimen; adeno-associated, 438–439, 442
laboratory features/objective testing, CODOX-M/IVAC regimen; adenoviral, 438
2269–2273, 2270f, 2272f COPP regimen; EPOCH regimen; lentiviral, 439, 443
in liver disease, 2192, 2193t, 2194–2195 HyperCVAD regimen; MOPP retroviral, 439
after liver transplantation, 2195 regimen; R-CVP regimen; Stanford self-inactivating, 437
in myeloma, 1741, 1756–1757 V regimen VISA. See Mitochondrial antiviral signaling
in paroxysmal nocturnal hemoglobinuria, for acute lymphoblastic leukemia, 1515, protein (MAVS)
580 1516, 1517 Vitamin A, 335, 652t
during pregnancy, 123 adverse effects, 325–326, 1519t Vitamin A deficiency, 651
prophylaxis, 2268 for α-heavy-chain disease, 1808 Vitamin B (riboflavin), 652t, 793, 2388
2
risk factors, 2268t for blast crisis in chronic myelogenous Vitamin B (riboflavin) deficiency, 651–652
2
therapy. See also specific drugs leukemia, 1466 Vitamin B , 652t
6
anticoagulants for Burkitt lymphoma, 1676 Vitamin B deficiency, 651
6
adverse effects, 2277 for diffuse large B-cell lymphoma, 1629t Vitamin B (cyanocobalamin), 588, 588f,
12
in cancer patients, 2276–2277 for follicular lymphoma, 1645t, 1646 589, 592f, 1448. See also Cobalamin
contraindications, 2273 for γ-heavy-chain disease, 1806 Vitamin B deficiency. See Cobalamin
12
duration, 2276 for immune thrombocytopenia, 2003, deficiency
objective and principles, 2273 2007 Vitamin C (ascorbic acid)
oral, 2274–2276, 2275t mechanism of action, 325 blood levels, 652t
parenteral, 2273–2274 for μ-heavy-chain disease, 1810 for Chédiak-Higashi syndrome, 1020
in pregnancy, 580, 2277 for myeloma, 1750, 1752t for erythropoietic protoporphyria, 899
regimens, 2273, 2274t for NK/T-cell lymphoma, 1702 hemolytic anemia and, 708
fibrinolytic, 2277–2278, 2313t pharmacology, 325–326 for hereditary methemoglobinuria, 793
inferior vena cava filter, 2278 resistance to, 319t for TET protein activity enhancement, 170
thrombophilia testing in, 2228. See also stomatocytosis and, 684 Vitamin C (ascorbic acid) deficiency
Hereditary thrombophilia for thrombotic thrombocytopenic (scurvy), 652, 1986, 2108, 2108f
Verapamil, 2079 purpura, 2256–2257 Vitamin D, 335, 2245
Verruca peruviana, 818 for Waldenström macroglobulinemia, Vitamin E
Vertebroplasty, 1756 1794–1795 for abetalipoproteinemia, 681
Very-late-antigen. See under VLA Vinculin, 1832t, 1848 functions, 653

Kaushansky_index_p2393-2506.indd 2502 9/21/15 3:23 PM